PFE
Stock Details
PFE is Pfizer Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 47.51$. Average daily volumn in 3 months 17.74M. Market cap 249.53B
Stock symbol : PFE. Exchange : NYSE. Currency : USD Lastest price : 44.46$. Total volume : 24.36M. Market state POST Click reload if you want to check the lastest price on market!!!
Pfizer Inc. (PFE)
Last Price
44.46$Change
0.32Volume
24.36M
| Previous Close | 44.14 |
| Open | 44.25 |
| Day Range | 44.10-44.84 |
| Bid | 44.41 x 1.8k |
| Ask | 44.39 x 1.8k |
| Volume | 24.36M |
| Average Volume | 17.74M |
| Market Cap | 249.53B |
| Beta | 0.65 |
| 52 Week Range | 40.94-61.71 |
| Trailing P/E | 8.65 |
| Foward P/E | 0.75 |
| Dividend (Yield %) | 3.66% |
| Ex-Dividend Date | 2022-11-03 |
Financial Details
Organization
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 trea... tment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Market Cap:
249.53BRevenue:
81.29BTotal Assets:
181.48BTotal Cash:
1.94B
News about "Pfizer Inc."
Pfizer Inc. (NYSE:PFE) Shares Bought by Sandy Spring Bank
Source from : Defense World - 17 hours ago
Bank increased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 3.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.See details»
Pfizer's Prostate Cancer Drug Trial Meets Key Target
Source from : MarketWatch - 16 hours ago
By Dean Seal Pfizer Inc. said the Phase 3 trial studying its drug Talzenna as a treatment for metastatic castration-resistant prostate cancer reached ...See details»
There's No Escaping Pfizer Inc.'s (NYSE:PFE) Muted Earnings
Source from : YAHOO!Finance - 1 days ago
Pfizer Inc.'s (NYSE:PFE) price-to-earnings (or "P/E") ratio of 8.3x might make it look like a buy right now compared to the market in the United States, where around half of the companies have P/E ...See details»
Voyager Therapeutics: Pfizer Exercises One of Two Capsid Options >VYGR
Source from : MarketWatch - 16 hours ago
By Colin Kellaher Voyager Therapeutics Inc. on Tuesday said Pfizer Inc. exercised one of two options to license a novel capsid generated from its ...See details»
Pfizer Reports Positive Topline Results From Phase 3 TALZENNA Trial
Source from : Nasdaq - 16 hours ago
Pfizer Inc. (PFE) announced Tuesday positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib) plus XTANDI in men with metastatic castration-resistant prostate cancer or mCRPC ...See details»
Wedbush Securities Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)
Source from : Defense World - 17 hours ago
Wedbush Securities Inc. raised its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 1.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission ...See details»
Pfizer CEO tests positive for COVID for a second time
Source from : Reuters - 10 days ago
Sept 24 (Reuters) - Pfizer Inc (PFE.N) Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19. "I’m feeling well and symptom free," Bourla said in a statement.See details»
Pfizer to supply up to 6 mln COVID pill courses for lower income countries
Source from : Reuters - 12 days ago
REUTERS/Dado Ruvic/Illustration/File Photo Sept 22 (Reuters) - Pfizer Inc (PFE.N) said on Thursday it would supply up to 6 million courses of its COVID-19 antiviral treatment to NGO Global Fund ...See details»
Pfizer Inc.'s (NYSE:PFE) Earnings Are Not Doing Enough For Some Investors
Source from : Yahoo Finance - 5 days ago
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 14x, you may consider Pfizer Inc. (NYSE:PFE) as an attractive investment with its 8.5x P/E ratio.See details»
Are Pfizer Inc.'s (NYSE:PFE) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Source from : Nasdaq - 13 days ago
Is Pfizer Efficiently Re-investing Its Profits ... of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative forces ...See details»
Pfizer Inc.'s (NYSE:PFE) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Source from : Yahoo - 13 days ago
It is hard to get excited after looking at Pfizer's (NYSE:PFE) recent performance, when its stock has declined 8.9% over the past month. But if you pay close attention, you might find that its key ...See details»
Pfizer Requests Clearance for Children’s Covid-19 Booster
Source from : Wall Street Journal - 8 days ago
Pfizer Inc. and BioNTech SE asked U.S. health regulators to clear use of their updated Covid-19 booster in children 5 years to 11 years. The companies made the request on Monday as retooled shots ...See details»
Pfizer Inc Company Profile, Facts | Competitive Intelligence Report – Market.us
Source from : PharmiWeb - 13 days ago
Pune, Maharashtra, India, September 21 2022 (Wiredrelease) Prudour Pvt. Ltd –:Pfizer Inc. is a pharmaceutical powerhouse that has been in operation for over 150 years. The company has developed and ...See details»
Covid-19 Vaccine Rollout Carries Lessons for Pharma Supply Chains, Says Pfizer Executive
Source from : Wall Street Journal - 10 days ago
The concentrated effort to develop, manufacture and distribute vaccines as the Covid-19 pandemic began to rage across the world highlighted the importance of the supply chain and helped set a ...See details»